CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 2015—The CE-IVD Oncomine Solid Tumor DNA kit from Thermo Fisher Scientific enables accurate and reliable multiplexed sequencing of formalin-fixed, paraffin-embedded tumor.
Based on the Ion Torrent AmpliSeq technology, the kit allows detection of single nucleotide somatic changes, inversions, insertions, and deletions using as little as 10 ng of FFPE DNA, enabling laboratory clinicians to analyze samples that may contain partially degraded or limited tumor material and generate reportable results from more samples than previously possible with lower acceptance thresholds for FFPE tumor DNA.
The panel was verified by leading clinicians from the OncoNetwork Consortium, which comprises twelve translational cancer research institutes, with a focus on colon and lung cancers. The kit captures regions of human somatic variants present in selected regions of cancer-related genes (EGFR, ALK, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, MET, DDR2, KRAS, PIK3CA, BRAF, AKT1, PTEN, NRAS, MAP2K1, STK11, NOTCH1, CTNNB1, SMAD4, FBXW7, TP53) for analysis using NGS technology.
Thermo Fisher Scientific, 760-603-7200